Le Lézard

Communiqués de presse par sujet : Essais cliniques / Découvertes médicales

1 2 3 4 5 6 7 8 9 10 11 12 13

5 septembre 2018

14:00
MELBOURNE, Fla., Sept. 5, 2018 /PRNewswire-PRWeb/ -- Erchonia, the World Leader in Low Level Laser technology, announces today that they have submitted data to the US FDA to support a 510(k) market clearance for Autism. The clinical trial was a...

13:38
Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Bausch Health Companies Inc. , today announced that the Journal of Cataract and Refractive Surgery (JCRS) has published results of a pivotal Phase 3, multicenter,...

11:04
According to a recent article in the International Journal of Spine Surgery, advanced decompression innovator Carevature's Drealtm device yields significantly better results in incidental dural tears, with 87% improvement compared to high-speed...

09:00
The 2019 Sternfels Prize for Drug Safety Discoveries application window opened today, according to contest officials. The Sternfels Prize recognizes research to reduce the risk associated with the real-world use of pharmaceuticals. The Prize was...

09:00
Strata Oncology, Inc. today announced it is participating as a CLIA-certified/accredited laboratory for the precision medicine cancer trial, NCI-Molecular Analysis for Therapy Choice (NCI-MATCH or EAY131). The objective of this ongoing phase II...

08:30
Neurotrope Inc. a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative and neurodevelopmental disorders, including Alzheimer's disease (AD), is announcing a collaboration with The Nemours / Alfred I. duPont...

08:14
Sangamo Therapeutics, Inc. today reported 16 week reductions in urinary glycosaminoglycans (GAGs), a key biomarker of Mucopolysaccharidosis Type II (MPS II) disease pathophysiology, in Cohort 2 of the Phase 1/2 CHAMPIONS Study evaluating SB-913. ...

08:05
BioCardia®, Inc. , a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that additional data from the open label, roll-in cohort of the ongoing Phase III CardiAMPtm Heart Failure Trial...

08:00
Trovagene, Inc. , a clinical-stage oncology therapeutics company, using a precision medicine approach to develop drugs for the treatment of leukemias, lymphomas and solid tumor cancers, today announced it has developed a method for predicting...

08:00
Harmony Biosciences, LLC (Harmony) today announced that it will present scientific data on its investigational product, pitolisant, which has been studied for the treatment of both excessive daytime sleepiness (EDS) and cataplexy in adult patients...

07:15
CannTrust Holdings Inc. ("CannTrust" or the "Company", TSX: TRST), one of Canada's leading and most trusted licensed producers of cannabis, announced today that it is pleased to collaborate with Hamilton Health Sciences and McMaster University...

07:00
Alpha Tau Medical, developer of a breakthrough alpha radiation cancer therapy, announced today that it has secured $29 million in private financing. The funding round was led by Shavit Capital, an Israeli private equity firm that specializes in...

07:00
Check-Cap Ltd. (the "Company" or "Check-Cap") , a clinical-stage medical diagnostics company engaged in the development of C-Scan®, an ingestible capsule for preparation-free, colorectal cancer (CRC) screening, today announced it has received...

07:00
ITUS Corporation and its research partner, Moffitt Cancer Center, today announced that a pre-IND meeting with the US FDA has been scheduled on Tuesday, October 16, 2018.  The meeting is to discuss numerous aspects of the planned clinical trial of...

07:00
NanoViricides, Inc. (the "Company"), a global leader in developing nanomedicines to attack viruses, announced today that  it will be presenting at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co.,...

03:16
BerGenBio ASA (OSE:BGBIO) announces that the company and its collaborators will present interim clinical data from its Phase II clinical development programme with bemcentinib (BGB324), a first-in-class highly selective oral AXL inhibitor, in...

03:00
Forendo Commences Phase Ia Study for FOR-6219 for Endometriosis  Forendo Pharma, a clinical stage drug development company focusing on novel treatments in women's health, today announces that it has raised an additional ?4 million of funding from...

00:29
A new Israel-Australia research centre involving a major collaboration with Monash University will be officially launched today in Tel Aviv, Israel. The Sagol Center for Epigenetics of Metabolism and Aging cements the relationship between Monash...


4 septembre 2018

21:57
MicroPort Scientific Corporation (« MicroPort® », HK : 0853) a annoncé aujourd'hui que les résultats de l'essai clinique sur son système d'endoprothèse coronarienne à élution ciblée de rapamycine Firehawk® (« Firehawk® »), qui a conduit à essai...

17:29
US WorldMeds and Salix Pharmaceuticals, one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases and a wholly owned subsidiary of Bausch Health Companies Inc. , will...

15:00
MicroPort Scientific Corporation («?MicroPort®?», HK : 0853) a annoncé aujourd'hui que les résultats de l'essai clinique concernant son système d'endoprothèse coronarienne à élution ciblée de rapamycine Firehawk® («?Firehawk®?»), qui a conduit un...

12:20
Mild traumatic brain injury (mTBI), commonly called a concussion, affects millions of children and teens each year. This injury can lead to short- or long-term problems affecting how a child thinks, acts, learns and feels. Released today, a new CDC...

09:00
AbbVie , a research-based global biopharmaceutical company, today announced that it will present new data across investigational medicines and HUMIRA® (adalimumab) at the 27th European Academy of Dermatology and Venereology (EADV) Congress, September...

09:00
SillaJen, Inc., (KOSDAQ:215600), a clinical-stage, biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, and Lee's Pharmaceutical Holdings Ltd., announced the first patient has been enrolled in China in...

08:50
Creative Medical Technology Holdings, Inc. announced today an update of its activities. CaverStemTM: Domestic recruitment, vetting and training of physicians on the CaverStemTM program for the use of the patients own stem cells for the treatment of...

08:01
The WIRB-Copernicus Group®'s (WCGtm) Clinical Services Division has partnered with Inspire, the largest online community of patients and caregivers, to make clinical research more accessible to all patients, especially those suffering from rare and...

08:00
Today, Eiger BioPharmaceuticals, Inc. , a company focused on the development and commercialization of targeted therapies for rare diseases, announced it has received minutes from a pre-investigational new drug (pre-IND) meeting with the Division of...

07:00
Phagenesis Ltd, a pioneering leader in the treatment of dysphagia, is pleased to announce today the publication of its most recent randomised controlled trial (PHAST-TRAC) in the journal Lancet Neurology. Reinhard Krickl, CEO of Phagenesis,...

07:00
Check-Cap Ltd. (the "Company" or "Check-Cap") , a clinical-stage medical diagnostics company engaged in the development of C-Scan®, an ingestible capsule-based device for preparation-free, colorectal cancer (CRC) screening, today announced the...

06:15
BiondVax Pharmaceuticals Ltd. , developer of the M-001 universal influenza vaccine candidate, reported today it will present at the Influenza 2018 Oxford conference at the University of Oxford. Joshua Phillipson,...

06:00
Soligenix, Inc. (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today publication of extended stability...

03:00
Miracor Medical SA (Miracor Medical) today announced the final closing of the Series D financing round of ?30M. The Series D capital will be used to further develop and commercialize the PiCSO® Impulse System. The Series-D round was led by Ming...

02:00
Phagenesis Ltd, leader pionnier dans le traitement de la dysphagie, est heureuse d'annoncer aujourd'hui la publication de son dernier essai randomisé contrôlé (PHAST-TRAC) dans le journal Lancet Neurology. Reinhard Krickl, PDG de Phagenesis, a...

02:00
Phagenesis Ltd, a pioneering leader in the treatment of dysphagia, is pleased to announce today the publication of its most recent randomised controlled trial (PHAST-TRAC) in the journal Lancet Neurology. Reinhard Krickl, CEO of Phagenesis,...


3 septembre 2018

19:13
MicroPort Scientific Corporation ("MicroPort®", HK:0853) announced today that the clinical trial results for its Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®") which conducted a multi-center, randomized controlled trial called...

04:00
VitalneXt BV today announces positive top-line results of a recently completed clinical study on its innovative medical nutrition (Vital01) to treat malnourished people. These were presented at the 40th Congress of 'the European Society for Clinical...


31 août 2018

18:45
An integrated analysis of one phase 2 and two phase 3 clinical trials published today in The Lancet found that the investigational medication, brexanolone injection 90 µg/kg/h (formerly SAGE-547 injection), demonstrated a reduction in depressive...

16:13
Kodiak Sciences Inc., a clinical stage biopharmaceutical company specializing in novel therapeutics to treat high prevalence ophthalmic diseases, today announced that enrollment of patients in the company's phase 1 safety and tolerability study has...

07:30
Amneal Pharmaceuticals, Inc. , a specialty pharmaceutical company, today announced a 5-year supply and distribution agreement with American Regent for the only preservative-free generic alternative to Makena® (hydroxyprogesterone caproate injection,...

00:04
XingImaging LLC, a radiopharmaceutical production and positron emission tomography (PET) acquisition company operating in Mainland China announced today that they are using PET Imaging to support multi-center Alzheimer's disease (AD) clinical trials...


30 août 2018

09:00
Emerald Lake Safety ("ELS"), an independent group researching ways to reduce the dangerous side effects associated with prescription pharmaceuticals, will present three posters on Sept. 23-25 at the 2018 American College of Clinical Pharmacology...

09:00
Regen BioPharma Inc. and , has identified a series of small molecule drugs that inhibit NR2F6. Regen's screening process demonstrated that its recently identified novel chemical compounds appear to inhibit NR2F6 and show potential for treating...

07:00
REGENXBIO Inc. , a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced it is developing a new product candidate,...

03:30
Les résultats de l'étude de suivi de 36 mois, OPTIMIST, montrent que BlueWind Renovatm est un système minimalement invasif sûr qui génère des améliorations durables et significatives pour les patients souffrant d'hyperactivité vésicale   BlueWind...

03:30
Results from 36-month OPTIMIST Follow-Up study show BlueWind Renovatm is a safe, minimally invasive system that offers durable and significant improvements for Over Active Bladder patients  BlueWind Medical, developer of the RENOVA iStimtm, an...


29 août 2018

23:44
The American offshoot of Australian biotech Noxopharm, Nyrada, believes it is within reach of achieving a major advance in the treatment of cardiovascular disease. It has made important progress with a drug candidate known as NYX-330 that Nyrada...

18:05
COLUMBUS, Ohio, Aug. 29, 2018 /PRNewswire-PRWeb/ -- Bryan Lindsey has solidified an agreement to invest an undisclosed amount of funding in ChromoCaretm, a leading genetics-testing firm that has developed a proprietary test and multifactorial...

15:30
Ensuring that food is safe and truthfully labeled is one of our fundamental responsibilities at the U.S. Food and Drug Administration. Consumers deserve accurate information about the food they eat and how it can affect their health and nutrition....

14:16
Ardelyx, Inc. , today announced that the novel mechanism of action for tenapanor for the treatment of hyperphosphatemia, or elevated serum phosphorus, has been published in the peer-reviewed journal Science Translational Medicine. Tenapanor,...

12:00
Today the Grace Science Foundation ("GSF") announced the creation of the world's first and only NGLY1 Deficiency registry, which provides invaluable resources to the medical community racing to find a cure for this rare genetic disorder. So far, the...

1 2 3 4 5 6 7 8 9 10 11 12 13